ReviewRecent patents on inflammation & allergy drug discovery2009
Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response.
Review in Recent patents on inflammation & allergy drug discovery, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- A Validation Argument for a Simulation-Based Training Course Centered on Assessment, Recognition, and Early Management of Pediatric Sepsis.Simulation in healthcare : journal of the Society for Simulation in Healthcare · 2018Trial
- Mesenchymal Stem Cells and Their Extracellular Vesicles Are a Promising Alternative to Antibiotics for Treating Sepsis.Bioengineering (Basel, Switzerland) · 2024Review
- Dexmedetomidine attenuates inflammation and organ injury partially by upregulating Nur77 in sepsis.Immunity, inflammation and disease · 2023Article
- Inflammasome-mediated GSDMD activation facilitates escape of Candida albicans from macrophages.Nature communications · 2021Article
- Quality Control Measures and Validation in Gene Association Studies: Lessons for Acute Illness.Shock (Augusta, Ga.) · 2020Review
- In vitro and molecular docking studies of an anti-inflammatory scaffold with human peroxiredoxin 5 and tyrosine kinase receptor.Bioinformation · 2020Article
- Resolvin D1 Promotes SIRT1 Expression to Counteract the Activation of STAT3 and NF-κB in Mice with Septic-Associated Lung Injury.Inflammation · 2018Article
- LpA-II:B:C:D:E: a new immunochemically-defined acute phase lipoprotein in humans.Lipids in health and disease · 2018Article
- Systemic blockade of P2X7 receptor protects against sepsis-induced intestinal barrier disruption.Scientific reports · 2017Article
- Sepsis in Pediatric Cardiac Intensive Care.Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies · 2016Review
- Effectiveness of Multiple Blood-Cleansing Interventions in Sepsis, Characterized in Rats.Scientific reports · 2016Article
- Inhibiting IκBβ-NFκB signaling attenuates the expression of select pro-inflammatory genes.Journal of cell science · 2015Article
- Immune activation efficacy of indolicidin is enhanced upon conjugation with carbon nanotubes and gold nanoparticles.PloS one · 2015Article
- Synthesis and biological evaluation of novel indole-2-one and 7-aza-2-oxindole derivatives as anti-inflammatory agents.Drug design, development and therapy · 2014Article
- Role of biphasic changes in splenic dendritic cell activity in a mouse model of multiple organ dysfunction syndrome.International journal of clinical and experimental pathology · 2014Article
- Inhibition of IKKβ in enterocytes exacerbates sepsis-induced intestinal injury and worsens mortality.Critical care medicine · 2013Article
- Effects of dexmedetomidine on early and late cytokines during polymicrobial sepsis in mice.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2013Article
- Serum cytokines associated with severity and complications of kala-azar.Pathogens and global health · 2013Article
- Synthesis and Anti-inflammatory Evaluation of Novel Benzimidazole and Imidazopyridine Derivatives.ACS medicinal chemistry letters · 2013Article
- Pediatric sepsis: preparing for the future against a global scourge.Current infectious disease reports · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Sepsis is currently the 10(th) leading cause of death overall and accounts for significant healthcare expenditures in the developed world. There are now more deaths attributable to sepsis than coronary artery disease, stroke, or cancer, and it is widely believed that the incidence of sepsis and sepsis-related mortality will continue to rise. Based on these sobering statistics, there is great interest in identifying novel treatments for managing critically ill children and adults with sepsis. Unfortunately, to date, there have been very few successful therapeutic agents employed in the clinical setting. Despite these disappointing results, new therapeutic agents continue to be identified, and there is reason for optimism and hope for the future. Herein, we will briefly review several novel therapeutic adjuncts for the management of critically ill patients with sepsis. We will largely focus on those therapies that directly target the host inflammatory response, specifically those that result in activation of the transcription factor, nuclear factor (NF)-kappaB. We will also reference some of the patents recently filed that pertain to the host innate immune response and sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.